|
Volumn 30, Issue 4, 1998, Pages 1468-1469
|
Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation
a a a a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
CYCLOSPORIN A;
INOLIMOMAB;
LYMPHOCYTE ANTIBODY;
MONOCLONAL ANTIBODY;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
OKT 3;
TACROLIMUS;
THYMOCYTE ANTIBODY;
CONFERENCE PAPER;
CONTROLLED STUDY;
DRUG INDICATION;
GRAFT REJECTION;
GRAFT SURVIVAL;
HEPATITIS C;
HEPATITIS C VIRUS;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
LIVER CIRRHOSIS;
LIVER TRANSPLANTATION;
MAJOR CLINICAL STUDY;
POSTOPERATIVE COMPLICATION;
PRIORITY JOURNAL;
RECURRENT DISEASE;
REOPERATION;
ANTIBODIES, MONOCLONAL;
CYCLOSPORINE;
GRAFT REJECTION;
HEPATITIS C;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
LIVER CIRRHOSIS;
LIVER TRANSPLANTATION;
METHYLPREDNISOLONE;
MUROMONAB-CD3;
MYCOPHENOLIC ACID;
RECEPTORS, INTERLEUKIN-2;
RECURRENCE;
REOPERATION;
RETROSPECTIVE STUDIES;
SURVIVAL RATE;
TACROLIMUS;
TIME FACTORS;
|
EID: 0031833485
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/S0041-1345(98)00319-4 Document Type: Conference Paper |
Times cited : (10)
|
References (14)
|